This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin

Many investors have eyed the previously presented ganetespib data with a good amount of skepticism, in part because claims the drug would work better in certain targeted subsets of lung cancer patients (elevated LDH or KRAS mutants) don't appear to have panned out. Synta is now positioning ganetespib as a more conventional add-on to chemotherapy for a broader swath of patients. Whether Synta is just throwing a Hail Mary or there's legitimate reason for optimism with ganetespib won't be decided for awhile, but the ASCO meeting should give us some additional clues.

I don't know the exact reason behind the FDA's delayed approval decision on Zogenix's (ZGNX - Get Report) painkiller Zohydro (an extended release formulation of hydrocodone that doesn't contain acetaminophen.) I am fairly confident that whenever FDA does get around to deciding Zohydro's fate -- Zogenix said a decision could come this summer -- the news will be bad.

Bottom line: FDA is no longer approving painkillers with abuse potential. Zohydro is abusable, therefore will be rejected.

I agree with the bearish take on Zogenix and Zohydro published last week by Jake King at PropThink.

Excellent decision. Speaking of Sarepta Therapeutics (SRPT - Get Report), here are my two, new favorite eteplirsen data slides, unveiled by CEO Chris Garabedian during his presentation last week at a healthcare investor conference. He also spoke about them on Thursday's first-quarter conference call.

The first slide, showing studies in which untreated kids with Duchenne muscular dystrophy decline on the six-minute walk test, supports the decline in walk distance recorded by placebo patients in the phase II study.

The second slide shows, for the first time, the eteplirsen data on a per-patient basis. Look at the remarkable consistency in six-minute walk scores.

Sarepta plans to submit additional information on eteplirsen to FDA before the end of May, with the hope that a follow-up meeting to discuss the accelerated approval filing can be scheduled at the end of the second quarter. I'm still expecting FDA to allow Sarepta to file for accelerated approval, which means eteplirsen will be approved.

No. We had two pieces of expected news from Arena Pharmaceuticals (ARNA) in the past week: The rejection of Belviq by European regulators and the completion of the long-delayed DEA scheduling that will finally allow the weight-loss pill to launch next month. The latter did not produce the "mother of all short squeezes" envisioned by the Arena longs because investors shorting (or planning to short) Arena want Belviq to launch. Weak efficacy and questionable heart safety plus big out-of-pocket expense for patients will equal poor Belviq sales.

Omthera Pharmaceuticals' (OMTH) market value ($166 million) is cheap relative to Amarin ($1 billion market value). That's about the most positive thing I can think to say about Omthera. I struggle to be excited about a third, prescription fish-oil pill for lowering trigylcerides. Amarin (AMRN) is having enough troubles selling Vascepa, making it hard to see how Omthera would have any better luck with its Epanova pill.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ZGNX $10.25 0.00%
AMRN $1.83 0.00%
RPRX $2.37 0.00%
SNTA $0.40 0.00%
SRPT $14.19 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs